Related Experiment Video

Updated: Jul 30, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Adriamycin and X-radiation effects upon an experimental solid tumor resistant to therapy

R Rowley, M Bacharach, H A Hopkins

    International Journal of Radiation Oncology, Biology, Physics
    |August 1, 1979
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
    09:45

    Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

    Published on: August 21, 2019

    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
    06:20

    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

    Published on: March 11, 2021

    Related Experiment Videos

    Last Updated: Jul 30, 2026

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
    09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
    09:45

    Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

    Published on: August 21, 2019

    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
    06:20

    Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

    Published on: March 11, 2021

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    How increased heifer growth rate and reduced dairy cow replacement rate can improve farm economy and reduce greenhouse gas emissions - a win to win situation?

    Animal : an international journal of animal bioscience·2024

    Liver fluke in beef cattle - Impact on production efficiency and associated greenhouse gas emissions estimated using causal inference methods.

    Preventive veterinary medicine·2022

    Evaluation of amoxicillin, metronidazole and gentamicin dosage regimens for use in antibiotic prophylaxis in colorectal surgery.

    The Journal of antimicrobial chemotherapy·2021

    Short communication: Identifying key parameters for modelling the impacts of livestock health conditions on greenhouse gas emissions.

    Animal : an international journal of animal bioscience·2021

    The Stirling Protocol - Putting the environment at the heart of prosperity and social inclusion.

    The Science of the total environment·2020

    Net benefits of smallholder dairy cattle farms in Senegal can be significantly increased through the use of better dairy cattle breeds and improved management practices.

    Journal of dairy science·2020

    Acute radiation side effects of proton versus photon therapy following surgery for early breast cancer, a sub-study of the randomised controlled DBCG Proton Trial.

    International journal of radiation oncology, biology, physics·2026

    Particle Beam Radiotherapy for Gynecologic Cancers: A Scoping Review and Expert Opinion by the Particle Therapy Cooperative Group - Gynecologic Subcommittee.

    International journal of radiation oncology, biology, physics·2026

    An exploratory analysis of the association between progesterone use and tumor-related visual deficit in women with meningioma.

    International journal of radiation oncology, biology, physics·2026

    Clinical Outcomes of Minibeam Radiotherapy for Superficial Skin and Soft Tissue Malignancies.

    International journal of radiation oncology, biology, physics·2026

    Explainable dual-task deep learning model for recurrence prediction and dose-sensitive region identification in HNC radiotherapy.

    International journal of radiation oncology, biology, physics·2026

    Multi-model RBE and dose-averaged LET optimized carbon ion radiotherapy for sacral chordoma: results of the first year of clinical application.

    International journal of radiation oncology, biology, physics·2026

    Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer with Sequential Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature.

    Case reports in oncology·2026

    TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

    iScience·2026

    Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.

    iScience·2026

    Hierarchical ROS-scavenging hydrogel system for coordinating the modulation of RGC necroptosis and oxidative stress in an acute glaucoma model.

    Bioactive materials·2026

    Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?

    Cureus·2026

    Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.

    Journal of pharmaceutical analysis·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us